Thrombotic events during long-term follow-up of obstetric antiphospholipid syndrome patients

Abstract

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by arterial and/or venous thromboses and/or pregnancy-associated morbidity. Some patients develop only obstetric complications (obstetric APS), but data on the frequency of thrombotic events during the follow-up of these patients are scarce. This study was undertaken to evaluate the rate of thrombotic events after obstetric APS diagnosis according to the 2006 revised criteria. In total, 32 obstetric APS patients were retrospectively studied, with mean follow-up of 50 ± 37 months. After delivery, aspirin was prescribed to all patients as primary thrombosis prevention. The thrombosis rate was 3.3/100 patient-years and was 4.6, 4.5 and 10/100 patient-years when we considered at least two antiphospholipid antibody positivities (among lupus anticoagulant, anticardiolipin and anti-β2-glycoprotein-I), antinuclear antibody positivity or systemic lupus erythematosus-associated APS patients, respectively. The thrombosis rate was high after obstetric APS diagnosis, even for patients taking aspirin. Larger, prospective studies are needed to confirm this high frequency and determine the associated risk factors.

Keywords

antiphospholipid syndrome pregnancy complications thrombosis

Get full access to this article

View all access options for this article.

References

Miyakis

Lockshin

Atsumi

. International Consensus Statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.

Cervera

Khamashta

Shoenfeld

. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2009; 68: 1428–1432.

Erkan

Merrill

Yazici

Sammaritano

Buyon

Lockshin

. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum 2001; 44: 1466–1467.

Quenby

Farquharson

Dawood

Hughes

Topping

. Recurrent miscarriage and long-term thrombosis risk: a case-control study. Human Reprod 2005; 20: 1729–1732.

Hochberg

. for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

Brandt

Triplett

Alving

Scharrer

. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185–1190.

Wilson

Gharavi

Koike

. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309–1311.

Neville

Rauch

Kassis

. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. Thromb Haemost 2003; 90: 108–115.

Tincani

Andreoli

Casu

Cattaneo

Meroni

. Antiphospholipid antibody profile: implications for the evaluation and management of patients. Lupus 2010; 19: 432–435.

10.

Obermoser

Bitterlich

Kunz

Sepp

. Clinical significance of anticardiolipin and anti-beta2-glycoprotein I antibodies. Int Arch Allergy Immunol 2004; 135: 148–153.

11.

Danowski

de Azevedo

de Souza Papi

Petri

. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 2009; 36: 1195–1199.

12.

White

. The epidemiology of venous thromboembolism. Circulation 2003; 107(Suppl 1): 4–8.

13.

Martinelli

Mannucci

De Stefano

. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92: 2353–2358.